312 related articles for article (PubMed ID: 3130488)
1. Differential effects of recombinant interferons alpha, beta, and gamma on induction of human lymphokine (IL-2)-activated killer activity.
Sone S; Utsugi T; Nii A; Ogura T
J Natl Cancer Inst; 1988 May; 80(6):425-31. PubMed ID: 3130488
[TBL] [Abstract][Full Text] [Related]
2. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
3. Up- and down-regulation of human lymphokine (IL-2)-activated killer cell induction by monocytes, depending on their functional state.
Nii A; Sone S; Utsugi T; Yanagawa H; Ogura T
Int J Cancer; 1988 Jan; 41(1):33-40. PubMed ID: 2826345
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes.
Singh SM; Sone S; Inamura N; Ogura T
Int J Cancer; 1989 Jul; 44(1):170-6. PubMed ID: 2663733
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity of human lymphokine (IL-2)-activated killer (LAK) precursors and regulation of their LAK induction by blood monocytes.
Sone S; Inamura N; Nii A; Ogura T
Int J Cancer; 1988 Sep; 42(3):428-34. PubMed ID: 3262092
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer (LAK) cells: interferon-gamma synergizes with interleukin-2 to induce LAK cytotoxicity in homogeneous leukemic preparations.
Kaufmann Y; Davidsohn J; Levanon M; Icekson I; Revel M; Ramot B
Clin Immunol Immunopathol; 1991 Feb; 58(2):278-88. PubMed ID: 1898716
[TBL] [Abstract][Full Text] [Related]
7. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
8. Effects of human alveolar macrophages on the induction of lymphokine (IL 2)-activated killer cells.
Sone S; Utsugi T; Nii A; Ogura T
J Immunol; 1987 Jul; 139(1):29-34. PubMed ID: 3495601
[TBL] [Abstract][Full Text] [Related]
9. Effects of tumour necrosis factor-alpha (TNF-alpha), IL-1 beta and monocytes on lymphokine-activated killer (LAK) induction from natural killer (NK) cells and T lymphocytes.
Yoneda K; Osaki T; Yamamoto T; Ueta E
Clin Exp Immunol; 1993 Aug; 93(2):229-36. PubMed ID: 8348749
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
Teichmann JV; Ludwig WD; Thiel E
Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
[TBL] [Abstract][Full Text] [Related]
11. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta.
Ochoa AC; Gromo G; Alter BJ; Sondel PM; Bach FH
J Immunol; 1987 Apr; 138(8):2728-33. PubMed ID: 2435804
[TBL] [Abstract][Full Text] [Related]
12. TNF-alpha and IFN-gamma reverse IL-4 inhibition of lymphokine-activated killer cell function.
Swisher SG; Economou JS; Holmes EC; Golub SH
Cell Immunol; 1990 Jul; 128(2):450-61. PubMed ID: 2113430
[TBL] [Abstract][Full Text] [Related]
13. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
14. In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.
Puri RK; Leland P
Clin Exp Immunol; 1991 Aug; 85(2):317-25. PubMed ID: 1713814
[TBL] [Abstract][Full Text] [Related]
15. Interferon is able to reduce tumor cell susceptibility to human lymphokine-activated killer (LAK) cells.
Grönberg A; Ferm M; Tsai L; Kiessling R
Cell Immunol; 1989 Jan; 118(1):10-21. PubMed ID: 2463094
[TBL] [Abstract][Full Text] [Related]
16. Synergism between alpha-interferon and interleukin-2-activated killer cells: in vitro studies.
Di Raimondo F; LaPushin R; Hersh EM
Acta Haematol; 1987; 78 Suppl 1():77-83. PubMed ID: 3124452
[TBL] [Abstract][Full Text] [Related]
17. Suppression of lymphokine-activated killer (LAK) cell induction mediated by interleukin-4 and transforming growth factor-beta 1: effect of addition of exogenous tumour necrosis factor-alpha and interferon-gamma, and measurement of their endogenous production.
Brooks B; Chapman K; Lawry J; Meager A; Rees RC
Clin Exp Immunol; 1990 Dec; 82(3):583-9. PubMed ID: 2124961
[TBL] [Abstract][Full Text] [Related]
18. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells.
Frey JR; Kamber M; Peck R
Lymphokine Res; 1987; 6(3):215-27. PubMed ID: 3114569
[TBL] [Abstract][Full Text] [Related]
19. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
[TBL] [Abstract][Full Text] [Related]
20. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
Blanchard DK; Djeu JY
J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
